Surgical therapies in metastatic colorectal cancer with a potential for cure

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 3, 2011, Pages 326-331

  Chua, Terence C ^a,b   Liauw, Winston ^c   Koong, Heng Nung ^d   Esquivel, Jesus ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST AGNES HOSPITAL   (United States)

^c ST GEORGE HOSPITAL   (Australia)

^d DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

cancer metastasis; colorectal cancer; liver metastases; lung metastases; peritoneal metastases; surgery

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; GENE MUTATION; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; LUNG RESECTION; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PERITONEUM METASTASIS; PROGNOSIS; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; FLUOROURACIL; HEPATECTOMY; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PERITONEAL NEOPLASMS; PNEUMONECTOMY;

EID: 79958286484     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181dbb9ad     Document Type: Review

References (88)

1. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005 (based on November 2007 SEER data submission). Bethesda, MD: National Cancer Institute, 2008. Available at: http://seer.cancer.gov/csr/ 1975-2005/. Updated 2008.
2. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130-160. (Pubitemid 351830299)
3. Andre T, Boni C, Mounedji-Boudiaf L, et al. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer I. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351. (Pubitemid 38702845)
4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer-see comment-. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
5. Colucci G, Gebbia V, Paoletti G, et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005;23:4866-4875. (Pubitemid 46223991)
6. Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26:2006 -2012.
7. Porschen R, Arkenau HT, Kubicka S, et al. Group AIOCS. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol. 2007;25:4217-4223. (Pubitemid 47548561)
8. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013-2019.
9. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-1676. (Pubitemid 46797946)
10. Jayne DG, Fook S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89:1545-1550. (Pubitemid 35404323)
11. Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63:364-367. (Pubitemid 19035034)
12. Seymour MT, Stenning SP, Cassidy J. Attitudes and practice in the management of metastatic colorectal cancer in Britain. Colorectal Cancer Working Party of the UK Medical Research Council. Clin Oncol (R Coll Radiol). 1997;9:248-251. (Pubitemid 27450101)
13. Golfinopoulos V, Salanti G, Pavlidis N, et al. Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol. 2007;8:898-911. (Pubitemid 47488054)
14. Kanemitsu Y, Kato T, Hirai T, et al. Preoperative probability model for predicting overall survival after resection of pulmonary metastases from colorectal cancer-see comment-. Br J Surg. 2004;91:112-120. (Pubitemid 38122060)
15. Massacesi C, Norman A, Price T, et al. A clinical nomogram for predicting long-term survival in advanced colorectal cancer. Eur J Cancer. 2000;36: 2044-2052.
16. Weiser MR, Landmann RG, Kattan MW, et al. Individualized prediction of colon cancer recurrence using a nomogram. J Clin Oncol. 2008;26:380-385. (Pubitemid 351171688)
17. Kattan MW, Gonen M, Jarnagin WR, et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg. 2008;247:282-287. (Pubitemid 351156771)
18. Bengmark S, Hafstrom L. The natural history of primary and secondary malignant tumours of the liver. Cancer. 1969;23:198-202.
19. Fong Y, Kemeny N, Paty P, et al. Treatment of colorectal cancer: hepatic metastasis. Semin Surg Oncol. 1996;12:219-252. (Pubitemid 26255863)
20. Kemeny N, Fata F. Arterial, portal or systemic chemotherapy for patients with hepatic metastasis of colorectal carcinoma. J Hepatobiliary Pancreat Surg. 1999;6:39-49.
21. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal metastases: biologic perspectives. Ann Surg. 1989;210:127-138. (Pubitemid 19188702)
22. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000;5(suppl 1):3-10. (Pubitemid 30225450)
23. Petrek JA, Minton JP. Treatment of hepatic metastases by percutaneous hepatic arterial infusion. Cancer. 1979;43:2182-2188. (Pubitemid 9246385)
24. Borner M, Laffer U, Ludwig C, et al. Effectiveness and low toxicity of hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer confined to the liver. The Swiss Group for Clinical and Epidemiological Cancer Research (SAKK). Ann Oncol. 1990;1:227-228. (Pubitemid 20218539)
25. Baden H, Andersen B. Survival of patients with untreated liver metastases from colorectal cancer. Scand J Gastroenterol. 1975;10:221-223.
26. Kato T, Yasui K, Hirai T, et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 2003;46(suppl 10):S22-S31. (Pubitemid 37266357)
27. Foster JH, Berman MM. Solid Liver Tumors. Major Problem in Clinical Surgery. Philadelphia, PA: W.B. Saunders Company; 1977:1-342.
28. Lise M, Da Pian PP, Nitti D, et al. Colorectal metastases to the liver: present status of management. Dis Colon Rectum. 1990;33:688-694. (Pubitemid 20251997)
29. Hunt TM, Carty N, Johnson CD. Resection of liver metastases from a colorectal carcinoma does not benefit the patient. Ann R Coll Surg Engl. 1990;72:199-205. (Pubitemid 20177446)
30. Wagner JS, Adson MA, Van Heerden JA, et al. The natural history of hepatic metastases from colorectal cancer. A comparison with resective treatment. Ann Surg. 1984;199:502-508. (Pubitemid 14105105)
31. Attiyeh FF, Wanebo HJ, Stearns MW. Hepatic resection for metastasis from colorectal cancer. Dis Colon Rectum. 1978;21:160-162. (Pubitemid 8341907)
32. Adson MA, Van Heerden JA. Major hepatic resections for metastatic colorectal cancer. Ann Surg. 1980;191:576-583. (Pubitemid 10107337)
33. Fortner JG, MacLean BJ, Kim DK, et al. The seventies evolution in liver surgery for cancer. Cancer. 1981;47:2162-2166. (Pubitemid 11098584)
34. Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol. 1997;15:938-946. (Pubitemid 27106275)
35. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309 -318; discussion 18-21.
36. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224:509 -520; discussion 20-22.
37. Azoulay D, Castaing D, Smail A, et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann Surg. 2000;231:480-486. (Pubitemid 30185853)
38. Hemming AW, Reed AI, Howard RJ, et al. Preoperative portal vein embolization for extended hepatectomy. Ann Surg. 2003;237:686-691; discussion 91-93.
39. Rivoire M, De Cian F, Meeus P, et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer. 2002;95:2283-2292. (Pubitemid 35351133)
40. Niu R, Yan TD, Zhu JC, et al. Recurrence and survival outcomes after hepatic resection with or without cryotherapy for liver metastases from colorectal carcinoma. Ann Surg Oncol. 2007;14:2078-2087. (Pubitemid 46988268)
41. Gleisner AL, Choti MA, Assumpcao L, et al. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg. 2008;143:1204-1212.
42. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825; discussion 25-27.
43. Ferrero A, Polastri R, Muratore A, et al. Extensive resections for colorectal liver metastases. J Hepatobiliary Pancreat Surg. 2004;11:92-96. (Pubitemid 38678822)
44. Hemming AW, Reed AI, Langham MR Jr, et al. Combined resection of the liver and inferior vena cava for hepatic malignancy. Ann Surg. 2004;239: 712-719; discussion 9-21.
45. Stewart GD, O'Suilleabhain CB, Madhavan KK, et al. The extent of resection influences outcome following hepatectomy for colorectal liver metastases. Eur J Surg Oncol. 2004;30:370-376. (Pubitemid 38528920)
46. Adam R, Miller R, Pitombo M, et al. Two-stage hepatectomy approach for initially unresectable colorectal hepatic metastases. Surg Oncol Clin N Am. 2007;16:525-536. (Pubitemid 46990942)
47. Mineo TC, Ambrogi V, Tonini G, et al. Long-term results after resection of simultaneous and sequential lung and liver metastases from colorectal carcinoma. J Am Coll Surg. 2003;197:386-391. (Pubitemid 38373297)
48. Barlow AD, Nakas A, Pattenden C, et al. Surgical treatment of combined hepatic and pulmonary colorectal cancer metastases. Eur J Surg Oncol. 2009;35:307-312.
49. Joosten J, Bertholet J, Keemers-Gels M, et al. Pulmonary resection of colorectal metastases in patients with or without a history of hepatic metastases. Eur J Surg Oncol. 2008;34:895-899.
50. Ike H, Shimada H, Togo S, et al. Sequential resection of lung metastasis following partial hepatectomy for colorectal cancer. Br J Surg. 2002;89:1164-1168. (Pubitemid 34989224)
51. Chua TC, Yan TD, Zhao J, et al. Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection. Eur J Surg Oncol. 2009;35:1299-1305.
52. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982-999.
53. Charnsangavej C, Clary B, Fong Y, et al. Selection of Patients for Resection of Hepatic Colorectal Metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1261-1268. (Pubitemid 44435791)
54. Nordlinger B, Van Cutsem E, Gruenberger T, et al; on behalf of the European Colorectal Metastases Treatment G. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009; 20:985-992.
55. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008;371:1007-1016. (Pubitemid 351392040)
56. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118-124.
57. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065-2072. (Pubitemid 46622116)
58. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26:1635-1641.
59. Khatri VP, Petrelli NJ, Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit? J Clin Oncol. 2005;23: 8490-8499.
60. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist. 2008;13:51-64. (Pubitemid 351206696)
61. McCormack PM, Attiyeh FF. Resected pulmonary metastases from colorectal cancer. Dis Colon Rectum. 1979;22:553-556.
62. McCormack PM, Burt ME, Bains MS, et al. Lung resection for colorectal metastases: 10-year results. Arch Surg. 1992;127:1403-1406.
63. Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg. 2002;124:1007-1013. (Pubitemid 35253251)
64. Welter S, Jacobs J, Krbek T, et al. Prognostic impact of lymph node involvement in pulmonary metastases from colorectal cancer. Eur J Cardiothorac Surg. 2007;31:167-172. (Pubitemid 46157271)
65. Koga R, Yamamoto J, Saiura A, et al. Surgical resection of pulmonary metastases from colorectal cancer: four favourable prognostic factors. Jpn J Clin Oncol. 2006;36:643-648. (Pubitemid 44697558)
66. Iizasa T, Suzuki M, Yoshida S, et al. Prediction of prognosis and surgical indications for pulmonary metastasectomy from colorectal cancer. Ann Thorac Surg. 2006;82:254-260.
67. Rena O, Casadio C, Viano F, et al. Pulmonary resection for metastases from colorectal cancer: factors influencing prognosis. Twenty-year experience. Eur J Cardiothorac Surg. 2002;21:906-912. (Pubitemid 34326392)
68. International-Registry-of-Lung-Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung Metastases. J Thorac Cardiovasc Surg. 1997;113:37-49.
69. Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84:324-338. (Pubitemid 46921128)
70. Treasure T. Pulmonary metastasectomy for colorectal cancer: weak evidence and no randomised trials. Eur J Surg Oncol. 2008;33:300-302.
71. Wilkins EW Jr, Head JM, Burke JF. Pulmonary resection for metastatic neoplasms in the lung. Experience at the Massachusetts General Hospital. Am J Surg. 1978;135:480-483.
72. McKenna RJ Jr, Houck W, Fuller CB. Video-assisted thoracic surgery lobectomy: experience with 1,100 cases. Ann Thorac Surg. 2006;81:421- 425; discussion 5-6.
73. Fang D, Zhang D, Huang G, et al. Results of surgical resection of patients with primary lung cancer: a retrospective analysis of 1,905 cases. Ann Thorac Surg. 2001;72:1155-1159. (Pubitemid 32937996)
74. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88:358-363. (Pubitemid 30051820)
75. Koppe MJ, Boerman OC, Oyen WJG, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212-222. (Pubitemid 43185440)
76. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. New Engl J Med. 2004;351:337-345. (Pubitemid 38944402)
77. Spratt JS, Adcock RA, Muskovin M, et al. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40:256-260. (Pubitemid 10140145)
78. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221:29-42.
79. Sugarbaker PH. Peritoneal Carcinomatosis: Drugs and Diseases. Boston, MA: Kluwer; 1996.
80. Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737-3743. (Pubitemid 46606227)
81. Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284-3292. (Pubitemid 41103684)
82. Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol. 2006;24:4011-4019. (Pubitemid 46630752)
83. Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27:681-685.
84. Lo CH, Bohmer RD, Blomfield PI. An evidence-based approach: Sugarbaker protocol and pseudomyxoma peritonei of appendiceal origin. ANZ J Surg. 2008;78:327-328. (Pubitemid 351465466)
85. Chua TC, Yan TD, Saxena A, et al. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A multiinstitutional review of morbidity and mortality. Ann Surg. In press.
86. Pelz JO, Stojadinovic A, Nissan A, et al. Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. J Surg Oncol. 2009;99:9-15.
87. Poston GJ, Figueras J, Giuliante F, et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol. 2008;26:4828-4833.
88. Jimeno A, Messersmith WA, Hirsch FR, et al. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol. 2009;27: 1130-1136.